AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Optec International, Inc.

$0 +$0.00 (+30.77%)
OTC · 15 Sep 2026 13:55 UTC
Previous Close
$0
Day Range
$0 - $0
Year Range
$0$0
Market Cap
2.91M
AVG Volume
1.79M
Trailing/Forward PE
-4.25/-
PEG ratio
-0.04
Dividend Yield
-
Next Earnings Date
-
Primary Exchange
Other OTCUS
Revenue (USD)
025K50K75K100K201620172018
OPTI Revenue (USD) by year
PeriodRevenue (USD)
201891.11K
201724.2K
201630.88K
Net Income (USD)
-1.5M-1M-500K0201620172018
OPTI Net Income (USD) by year
PeriodNet Income (USD)
2018-1.32M
2017-10.01K
2016-32.93K
Operating Income (USD)
-200K-150K-100K-50K0201620172018
OPTI Operating Income (USD) by year
PeriodOperating Income (USD)
2018-171.58K
2017-10.01K
2016-32.93K
EBITDA (USD)
-1.5M-1M-500K0201620172018
OPTI EBITDA (USD) by year
PeriodEBITDA (USD)
2018-1.02M
2017-164.01K
2016-5.93K
Cash Flows (USD)
-300K-200K-100K0201620172018
OPTI Cash Flows (USD) by year
PeriodCash Flows (USD)
2018-281.81K
2017-8.63K
2016-24.18K
EPS (USD)
-0.04-0.03-0.02-0.010201620172018
OPTI EPS (USD) by year
PeriodEPS (USD)
2018-0.03
2017-0.02
2016-0
Expenses (USD)
050K100K150K201620172018
OPTI Expenses (USD) by year
PeriodExpenses (USD)
2018111.65K
201723.14K
201648.51K
Cash & Debt (USD)
0200K400K600KCashShort Term Debt201620172018
OPTI Cash & Debt (USD) by year
PeriodCash & Debt (USD)
201830.8K
2017342
20168.98K
Debt ratios
00.511.52201620172018
OPTI Debt ratios by year
PeriodDebt ratios
20180.02
20170.05
20161.8
Margins
0%20%40%60%80%201620172018
OPTI Margins by year
PeriodMargins
201835.94%
201771.07%
201661.13%
Return on Capital
-200%-100%0%100%200%201620172018
OPTI Return on Capital by year
PeriodReturn on Capital
2018115.59%
2017-93.67%
2016-159.09%
Shares Outstanding
020M40M60M201620172018
OPTI Shares Outstanding by year
PeriodShares Outstanding
20180
201752.94M
201652.94M
Book Value Per Share (USD)
0000020162017
OPTI Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
20170
20160
Total Assets (USD)
0200K400K600K800K201620172018
OPTI Total Assets (USD) by year
PeriodTotal Assets (USD)
2018626.37K
201717.69K
201625.7K
Employee Count
00.511.522018
OPTI Employee Count by year
PeriodEmployee Count
20181
PE Ratio
13500140001450015000med 14002.94Jan 18Jan 18Feb 18Feb 18Mar 18Mar 18Mar 18
OPTI PE Ratio by year
PeriodPE Ratio
Mar 1813652.53
Mar 1813652.53
Mar 1813652.53
Mar 1813622.19
Mar 1814201.66
Feb 1814201.66
Feb 1814201.66
Feb 1814201.66
Feb 1813652.53
Jan 1813652.53
Jan 1814259.31
Jan 1814259.31
Jan 1814691.64
Dec 1713804.22
Free Cash Flow Yield
-80%-60%-40%-20%0%med -8.53%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
OPTI Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-8.03%
Sep 26-8.03%
Sep 26-7.58%
Aug 26-7.58%
Aug 26-6.82%
Aug 26-6.82%
Aug 26-6.2%
Jul 26-7.58%
Jul 26-13.64%
Jul 26-10.49%
Jul 26-17.05%
Jul 26-19.49%
Jun 26-34.11%
Jun 26-45.48%
Jun 26-45.48%
Jun 26-34.11%
May 26-45.48%
May 26-34.11%
May 26-34.11%
May 26-27.29%
May 26-34.11%
Apr 26-34.11%
Apr 26-34.11%
Apr 26-34.11%
Apr 26-34.11%
Mar 26-34.11%
Mar 26-13.64%
Mar 26-6.5%
Mar 26-15.16%
Feb 26-15.16%
Feb 26-22.74%
Feb 26-27.29%
Feb 26-68.21%
Jan 26-34.11%
Jan 26-45.48%
Jan 26-10.49%
Jan 26-8.53%
Jan 26-10.49%
Dec 25-7.8%
Dec 25-6.2%
Dec 25-6.82%
Dec 25-8.03%
Nov 25-8.03%
Nov 25-5.93%
Nov 25-5.25%
Nov 25-11.37%
Oct 25-11.37%
Oct 25-8.53%
Oct 25-13.64%
Oct 25-11.37%
Oct 25-9.1%
Sep 25-9.74%
Sep 25-11.37%
Sep 25-12.4%
Sep 25-9.1%
Aug 25-9.1%
Aug 25-8.53%
Aug 25-8.53%
Aug 25-7.58%
Aug 25-10.49%
Jul 25-7.58%
Jul 25-10.49%
Jul 25-9.1%
Jul 25-10.49%
Jun 25-6.82%
Jun 25-8.53%
Jun 25-7.58%
Jun 25-6.82%
May 25-7.18%
May 25-6.2%
May 25-7.58%
May 25-5.46%
May 25-7.58%
Apr 25-5.46%
Apr 25-5.93%
Apr 25-5.25%
Apr 25-6.5%
Mar 25-6.2%
Mar 25-4.87%
Mar 25-6.82%
Mar 25-4.55%
Feb 25-4.55%
Feb 25-4.87%
Feb 25-4.55%
Feb 25-5.93%
Jan 25-9.74%
Jan 25-8.53%
Jan 25-9.41%
Jan 25-8.53%
Jan 25-6.5%
Dec 24-7.58%
Dec 24-10.49%
Dec 24-9.1%
Dec 24-6.82%
Nov 24-6.82%
Nov 24-6.82%
Nov 24-6.82%
Nov 24-6.82%
Nov 24-6.82%
Oct 24-7.18%
Price to Sales
0246med 2.31Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
OPTI Price to Sales by year
PeriodPrice to Sales
Sep 262.45
Sep 262.45
Sep 262.59
Aug 262.59
Aug 262.88
Aug 262.88
Aug 263.17
Jul 262.59
Jul 261.44
Jul 261.87
Jul 261.15
Jul 261.01
Jun 260.58
Jun 260.43
Jun 260.43
Jun 260.58
May 260.43
May 260.58
May 260.58
May 260.72
May 260.58
Apr 260.58
Apr 260.58
Apr 260.58
Apr 260.58
Mar 260.58
Mar 261.44
Mar 263.03
Mar 261.3
Feb 261.3
Feb 260.86
Feb 260.72
Feb 260.29
Jan 260.58
Jan 260.43
Jan 261.87
Jan 262.31
Jan 261.87
Dec 252.52
Dec 253.17
Dec 252.88
Dec 252.45
Nov 252.45
Nov 253.31
Nov 253.75
Nov 251.73
Oct 251.73
Oct 252.31
Oct 251.44
Oct 251.73
Oct 252.16
Sep 252.02
Sep 251.73
Sep 251.59
Sep 252.16
Aug 252.16
Aug 252.31
Aug 252.31
Aug 252.59
Aug 251.87
Jul 252.59
Jul 251.87
Jul 252.16
Jul 251.87
Jun 252.88
Jun 252.31
Jun 252.59
Jun 252.88
May 252.74
May 253.17
May 252.59
May 253.6
May 252.59
Apr 253.6
Apr 253.31
Apr 253.75
Apr 253.03
Mar 253.17
Mar 254.03
Mar 252.88
Mar 254.32
Feb 254.32
Feb 254.03
Feb 254.32
Feb 253.31
Jan 252.02
Jan 252.31
Jan 252.09
Jan 252.31
Jan 253.03
Dec 242.59
Dec 241.87
Dec 242.16
Dec 242.88
Nov 242.88
Nov 242.88
Nov 242.88
Nov 242.88
Nov 242.88
Oct 242.74
EV/EBITDA
02500500075001000012500med 11067.35Dec 16Jan 17Jan 17Feb 17Feb 17Mar 17Mar 17
OPTI EV/EBITDA by year
PeriodEV/EBITDA
Mar 172459.28
Mar 172459.28
Mar 172459.28
Mar 172459.28
Feb 172459.28
Feb 1711067.35
Feb 1711067.35
Feb 1711067.35
Jan 1711067.35
Jan 1711067.35
Jan 1711067.35
Jan 1711067.35
Dec 1611067.35
Price to Book
0246810med 4.57Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
OPTI Price to Book by year
PeriodPrice to Book
Sep 264.85
Sep 264.85
Sep 265.14
Aug 265.14
Aug 265.71
Aug 265.71
Aug 266.28
Jul 265.14
Jul 262.85
Jul 263.71
Jul 262.28
Jul 262
Jun 261.14
Jun 260.86
Jun 260.86
Jun 261.14
May 260.86
May 261.14
May 261.14
May 261.43
May 261.14
Apr 261.14
Apr 261.14
Apr 261.14
Apr 261.14
Mar 261.14
Mar 262.85
Mar 265.99
Mar 262.57
Feb 262.57
Feb 261.71
Feb 261.43
Feb 260.57
Jan 261.14
Jan 260.86
Jan 263.71
Jan 264.57
Jan 263.71
Dec 254.99
Dec 256.28
Dec 255.71
Dec 254.85
Nov 254.85
Nov 256.56
Nov 257.42
Nov 253.42
Oct 253.42
Oct 254.57
Oct 252.85
Oct 253.42
Oct 254.28
Sep 254
Sep 253.42
Sep 253.14
Sep 254.28
Aug 254.28
Aug 254.57
Aug 254.57
Aug 255.14
Aug 253.71
Jul 255.14
Jul 253.71
Jul 254.28
Jul 253.71
Jun 255.71
Jun 254.57
Jun 255.14
Jun 255.71
May 255.42
May 256.28
May 255.14
May 257.14
May 255.14
Apr 257.14
Apr 256.56
Apr 257.42
Apr 255.99
Mar 256.28
Mar 257.99
Mar 255.71
Mar 258.56
Feb 258.56
Feb 257.99
Feb 258.56
Feb 256.56
Jan 254
Jan 254.57
Jan 254.14
Jan 254.57
Jan 255.99
Dec 245.14
Dec 243.71
Dec 244.28
Dec 245.71
Nov 245.71
Nov 245.71
Nov 245.71
Nov 245.71
Nov 245.71
Oct 245.42
Optec International, Inc.
OPTI
Stockpicker

Video analysis: OPTI

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: OPTI

Optimi Health Establishes Discretionary Equity Facility

globenewswire.com · 14 Aug 2026

Optimi Health Establishes Discretionary Equity Facility

VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it has entered into a common shares purchase agreement (the “Purchase Agreement”) with Seven Knots, LLC (“Seven Knots”), establishing an equity line of credit (the “ELOC”) under which the Company has the right, but not the obligation, to sell to Seven Knots up to US$100 million of its common shares from time to time over the term of the facility.

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

globenewswire.com · 16 Jun 2026

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Two naturally derived finished drug products, at 1mg and 2mg, give research organizations the consistent, validated doses required for controlled studies New microdose formats extend Optimi's psilocybin range, which includes a 5mg formulation currently commercially prescribed for treatment-resistant depression in Australia under the country's Authorized Prescriber Scheme VANCOUVER, British Columbia, June 16, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage GMP pharmaceutical manufacturer of regulated psychedelic drug products, today announced it has completed production of two microdose psilocybin finished drug products, formulated at 1 mg and 2 mg dosages. The products are available to qualified, authorized clinical research organizations.

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.